NasdaqGM - Nasdaq Real Time Price USD

MannKind Corporation (MNKD)

Compare

6.85

+0.55

(+8.73%)

At close: December 20 at 4:00:02 PM EST

6.85

-0.00

(-0.01%)

After hours: December 20 at 7:57:44 PM EST

MannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 years

Long term investing can be life changing when you buy and hold the truly great businesses. While the best companies are...

Simply Wall St. 2 days ago

MNKD
+8.73%
MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

Company debt reduced by $194 millionCash position after closing will be in excess of $180 million DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today announced today that it has entered into separate, privately negotiated exchange agreements with certain holders (the “Holders”) of its 2.50% Convertible Senior Notes due 2026 (the “Notes”). Under the terms of the exchange agreements, the Holders agreed to exchange an aggregate pr

GlobeNewswire 4 days ago

MNKD
+8.73%
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes program progression DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, today announced six-month results from its Phase 3 INHALE-1 stu

GlobeNewswire 6 days ago

MNKD
+8.73%
CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

India has the 2nd highest burden of diabetes worldwideCDSCO decision follows existing approvals in the U.S.A. and BrazilMannKind expects to ship product for Cipla Ltd. by end of 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, and Cipla Ltd. announced today th

GlobeNewswire 11 days ago

MNKD
+8.73%
MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

MannKind ( NASDAQ:MNKD ) Third Quarter 2024 Results Key Financial Results Revenue: US$70.1m (up 37% from 3Q 2023). Net...

Simply Wall St. last month

MNKD
+8.73%
Q3 2024 MannKind Corp Earnings Call

Q3 2024 MannKind Corp Earnings Call

Thomson Reuters StreetEvents last month

MNKD
+8.73%
MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

MannKind Corp (MNKD) reports a 37% revenue increase, driven by Tyvaso DPI and Afrezza, while navigating market challenges and advancing its pipeline.

GuruFocus.com last month

MNKD
+8.73%
MannKind (MNKD) Q3 2024 Earnings Call Transcript

MNKD earnings call for the period ending September 30, 2024.

Motley Fool last month

MNKD
+8.73%
MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks last month

MNKD
+8.73%
MannKind (MNKD) Matches Q3 Earnings Estimates

MannKind (MNKD) delivered earnings and revenue surprises of 0% and 9.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

MNKD
+8.73%
MannKind: Q3 Earnings Snapshot

DANBURY, Conn. AP) — MannKind Corp. MNKD) on Thursday reported net income of $11.6 million in its third quarter.

Associated Press Finance last month

MNKD
+8.73%
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Conference Call to Begin Today at 4:30 p.m. (ET) 3Q 2024 Total revenues of $70M; +37% vs. 3Q 2023YTD 2024 Total revenues of $209M; +49% vs. YTD 2023YTD 2024 Net income of $20 million; Non-GAAP net income of $45 millionOrphan lung disease studies proceeding as planned MNKD-101 Phase 3 clinical trial expands globallyMNKD-201 Phase 1 successfully completed; Plan to meet with FDA in 1H 2025 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: M

GlobeNewswire last month

MNKD
+8.73%
MannKind to Present at 2024 UBS Healthcare Conference

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that Chief Executive Officer Michael Castagna, PharmD, and Chief Financial Officer Chris Prentiss will share updates during a fireside chat at the 2024 UBS Healthcare Conference in Rancho Palos Verdes

GlobeNewswire last month

MNKD
+8.73%
High Growth Tech Stocks To Watch In November 2024

Over the last 7 days, the United States market has dropped 1.6%, yet it remains up by an impressive 31% over the past year, with earnings expected to grow by 15% annually in the coming years. In this context of robust long-term growth potential, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation and adaptability within this dynamic environment.

Simply Wall St. last month

MNDY

FIVN

MNKD
+8.73%
MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Met primary objective demonstrating nintedanib DPI was safe and well toleratedParticipants did not experience adverse events typically reported with oral nintedanibExpect to meet with the FDA in 1H 2025 to advance MNKD-201 into the next phase of development DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients

GlobeNewswire last month

MNKD
+8.73%
MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?

MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks last month

MNKD
+8.73%
MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its third quarter 2024 financial results will be released after market close on Thursday, November 7, 2024. MannKind will host a webcast beginning at 4:30 p.m. Eastern Time to discuss the quarterly results and provide a business update. Participating in the conference call from MannKind will be Chief Executive Officer Michael Castagna, PharmD, and Chief Financi

GlobeNewswire last month

MNKD
+8.73%
First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its

GlobeNewswire last month

MNKD
+8.73%
MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ...

MannKind Corp (MNKD) reports a 49% revenue increase and advances in its promising drug pipeline despite a GAAP net loss.

GuruFocus.com 2 months ago

MNKD
+8.73%
Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks 2 months ago

MNKD
+8.73%

Performance Overview

Return	MNKD	S&P 500
YTD	+88.19%	+24.34%
1-Year	+75.19%	+24.38%
3-Year	+60.05%	+28.36%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

MannKind Corporation (MNKD)

MannKind (NASDAQ:MNKD) pulls back 3.8% this week, but still delivers shareholders fantastic 36% CAGR over 5 years

MannKind Corporation Announces Exchange of Convertible Notes for Stock and Cash

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

MannKind Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Q3 2024 MannKind Corp Earnings Call

MannKind Corp (MNKD) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

MannKind (MNKD) Q3 2024 Earnings Call Transcript

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

MannKind (MNKD) Matches Q3 Earnings Estimates

MannKind: Q3 Earnings Snapshot

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

MannKind to Present at 2024 UBS Healthcare Conference

High Growth Tech Stocks To Watch In November 2024

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Corp (MNKD) Q2 2024 Earnings Call Highlights: Record Revenue and Strategic Pipeline ...

Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings

Performance Overview